|
SERPINE1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
An important risk factor for CVD is the deregulation of the fibrinolytic system particularly high levels of expression of plasminogen activator inhibitor 1 (<i>Pai-1</i>).
|
31824324 |
2019 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
Of these genes, the adverse allele (or combinations) was same in nine (ADRB2, FV, HMOX1, IL6, MBL, MIF, NOD2, PCSK9, SERPINE1), and the effect appears to be in the same direction in both sepsis and cardiovascular disease.
|
30660782 |
2019 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
PAI-1 has been shown to play a role in a number of diverse pathologies including cardiovascular diseases, obesity and cancer and is therefore an attractive therapeutic target.
|
30733557 |
2019 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Identification of molecular events underlying senescence-associated PAI-1 expression in response to TGF-β1/<i>src</i> kinase/p53 signaling may provide novel targets for the therapy of cardiovascular disease.
|
31382626 |
2019 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
Further investigations are needed to test the safety and efficacy of PAI-1 as a pharmacological target in cardiovascular diseases.
|
30659821 |
2019 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
On multivariable analysis adjusted for potential confounders, H3Cit and cfDNA, along with plasminogen activator inhibitor-1 and concomitant cardiovascular disease, were predictors of CLT.
|
30992036 |
2019 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrated that the increase of sICAM-1, sVCAM-1 and PAI-1, together with decrease of omentin-1 led to a proinflammatory imbalance pointing to the presence of subclinical atherosclerosis, and improving CVD risk stratification in non-smoking patients at early stage MetS beyond traditional scores.
|
31349950 |
2019 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Trend analysis was applied to determine the correlation of plasma PAI-1 levels with lipid markers for cardiovascular disease and with the staging of histological features in the liver.
|
27764892 |
2018 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies have reported that plasminogen activator inhibitor-1 (PAI-1) serves an important role in cardiovascular disease risk, adiposity, insulin resistance and inflammation.
|
29844807 |
2018 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
In this regard, the greater CVD in Blacks than Whites have been partly attributed to other non-traditional CVD risk factors, such as subclinical inflammation (C-reactive protein), homocysteine, increased low-density lipoprotein oxidation, lipoprotein a, adiponectin, and plasminogen activator inhibitor-1, etc.
|
28912752 |
2017 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
Adipose tissue produces PAI-1, and pericardial fat is a CVD risk factor.
|
28504921 |
2017 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Using exome-wide data from 1,032 Ghanaian study participants, we tested for heterogeneity of correlation by genotype between PAI-1 and 4 CVD risk factors (body mass index, triglycerides, mean arterial pressure, and fasting glucose) under the hypothesis that loci involved in the relationship between PAI-1 and other risk factors will also modify their correlational structure.
|
28408189 |
2017 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
Methods We measured leukocyte telomere length (LTL) and plasma PAI-1 in 2560 American Indians who were free of overt cardiovascular disease (CVD) and participated in the Strong Heart Family Study (SHFS) clinical examination in 2001-2003.
|
28378522 |
2017 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
As both MDD and CVD are more prevalent in women than in men, and incidence of either condition is dramatically increased during reproductive milestones, we also explore hormonal and sex-specific associations between MDD, PAI-1 and CVD.
|
27246986 |
2017 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
Visceral adipose tissue produces more PAI-1 than subcutaneous adipose tissue: This increased production of PAI-1 from the visceral adipose tissue is one important link between visceral obesity and cardiovascular disease.
|
28605281 |
2017 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, the results revealed loureirin B as a PAI-1 inhibitor, adding a new pharmacological target for loureirin B and uncovering a novel mechanism underlying the antithrombotic property of Resina Draconis, which might be useful in the treatment of cardiovascular diseases such as thrombosis and fibrosis.
|
29234445 |
2017 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
Increased plasma plasminogen activator inhibitor-1 (PAI-1) level is considered a mechanistic pathway through which obesity contributes to increased cardiovascular disease risk.
|
27233154 |
2016 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A total of nine gene variants/polymorphisms - F5 (Leiden - R5 06Q, rs6025), F2 (20210G > A, rs1799963), F13A1 (rs5985" genes_norm="2162">V34L, rs5985), MTHFR (677C > T - rs1801133;rs771406104;rs1455404812;s771406104" genes_norm="1636;2244;4524">A222V, rs1801133), MTHFR (1298A > C - rs1801131" genes_norm="4524">E429A, rs1801131), FGB (-455G > A -c.-463G > A; rs1800790), SERPINE1 (PAI14G/5G - rs1799889), ACE (ACE I/D, rs1799752), ITGB3 (GPIIIa L33P, rs5918) and the APOE E2/E3/E4 alleles (rs7412, rs429358) - were genotyped in 200 newly diagnosed ischemic stroke (IS) patients, 165 patients with ischemic coronary heart disease (CHD) and 159 controls with no cerebroor cardiovascular disease (non-CVD).
|
27629735 |
2016 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
Plasminogen activator inhibitor 1 (PAI-1), a major modulator of the fibrinolytic system, is an important factor in cardiovascular disease (CVD) susceptibility and severity.
|
26322636 |
2015 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutation analyses were conducted using the real-time polymerase chain reaction method to screen six common mutations (Factor V G1691A, PT G20210A, Factor XIII V34L, MTHFR A1298C and C677T and PAI-1 -675 4G/5G) found in CVD panel.
|
24532105 |
2014 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
Height, weight, BMI, waist circumference, clinical and metabolic markers, adipokines, and inflammatory (PCR, IL-6, IL-8 and TNF-α) and CVD risk biomarkers (MPO, MMP-9, sE-selectin, sVCAM, sICAM, and PAI-1) were analyzed.
|
23624317 |
2013 |
|
SERPINE1
|
0.100 |
Biomarker
|
group |
BEFREE |
LTL resulted inversely correlated with family history of CVD (t = 2.70; p = 0.009), age (r = -0.238; p = 0.032), waist circumference (r = -0.256; p = 0.02), triglycerides (r = -0.218; p = 0.049), PAI-1 (r = -0.288; p = 0.009) and directly correlated with HDL-cholesterol (r = 0.316; p = 0.004) and EPC number (r = 0.358; p = 0.002).
|
21824757 |
2013 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found no evidence for an association between PAI-1 5G>4G and CVD risk.
|
22100658 |
2012 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PAI-1 attenuates fibrinolysis and increased levels of active PAI-1 have been associated with an increased risk for cardiovascular diseases.
|
22801256 |
2012 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Increased serum levels of plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6) and IL-18 have been reported to be associated with CVD.
|
21842238 |
2011 |